S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
OCUL · Ocular Therapeutix, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Ocular Therapeutix Inc (OCUL)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$6.49
-0.16
(-2.41%)
● At close: October 21 at 4:00:00 PM EDT
$6.42
-0.06
(-0.93%)
Overnight:
10:26:40 PM EDT
DAY'S RANGE
$6.49
$6.38
$6.74
52-WEEK RANGE
$6.49
$6.00
$16.44
What's happening
- OCUL is down 2.41% today, trading at $6.49. — Live quote
- Volume today (111,241) is well below its 3-month average of 2,995,560. (Finnhub fundamentals)
- Reports earnings on 2026-11-09 (after market close), 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.35 actual vs. $-0.40 estimated (+13.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 11
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (18 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
OCUL
-45.22%
vs S&P 500
-58.00%
1-YEAR RETURN
OCUL
-45.40%
vs S&P 500
-59.96%
6-MONTH RETURN
OCUL
-24.94%
3-MONTH RETURN
OCUL
-25.53%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.35
Est. $-0.40
BEAT +13.2%
2026-04-26 (Q1 2026)
$-0.40
Est. $-0.32
MISS -25.6%
2026-01-26 (Q4 2025)
$-0.29
Est. $-0.33
BEAT +12.7%
2025-10-26 (Q3 2025)
$-0.38
Est. $-0.37
MISS -1.6%
Valuation Measures & Ratios
Enterprise Value4$934.6M
Forward P/E5—
PEG Ratio6-0.44
Price / Sales (TTM1)28.06
Price / Book74.13
EV4 / Revenue17.95
EV4 / EBITDA—
Profit Margin-579.10%
Operating Margin-603.04%
Return on Equity (ROE8)-59.87%
Return on Assets (ROA9)-45.97%
Avg Volume (3M)2,995,560
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $2.21B | $1.88B | $2.14B | $1.61B | $1.23B |
| P/E | -7.25 | -6.48 | -8.98 | -7.60 | -5.90 |
| Price/Sales | 42.24 | 37.96 | 39.45 | 28.79 | 21.52 |
| Price/Book | 4.25 | 3.23 | 8.27 | 5.27 | 4.64 |
| EV/Revenue | 30.79 | 24.49 | 33.08 | 21.81 | 15.42 |
| EV/EBITDA | -5.25 | -4.19 | -7.39 | — | — |
| ROE | -58.57% | -49.85% | -92.08% | -69.34% | -78.66% |
| ROA | -45.37% | -39.57% | -57.87% | -47.00% | -51.53% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short29,412,673
Change from Prior Settlement-1.74%
% of Float—
Days to Cover (Short Ratio)7.25
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 0.1% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-16; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -579.1%. Finnhub fundamentals ↗
- Trailing 52-week price return is -45.4%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on OCUL
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.5M | $10.8M | $14.5M | $13.5M | $10.7M | $15.4M | $16.4M | $14.8M |
| Operating income | -$82.1M | -$93.3M | -$68.7M | -$67.6M | -$63.9M | -$46.0M | -$43.6M | -$31.6M |
| Net income | -$78.8M | -$88.6M | -$69.4M | -$67.8M | -$64.1M | -$36.5M | -$43.8M | -$64.8M |
| EPS (diluted) | $-0.35 | $-0.40 | $-0.38 | $-0.39 | $-0.38 | $-0.22 | $-0.26 | $-0.49 |
| EPS (basic) | $-0.35 | $-0.40 | $-0.38 | $-0.39 | $-0.38 | $-0.22 | $-0.26 | $-0.49 |
| Operating margin | -$609 | -$865 | -$472 | -$503 | -$597 | -$298 | -$265 | -$214 |
| Net margin | -$585 | -$822 | -$477 | -$504 | -$599 | -$237 | -$266 | -$439 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $671.3M | $732.5M | $808.1M | $410.9M | $451.3M | $405.9M | $457.9M | $490.4M |
| Total liabilities | $151.3M | $151.0M | $153.7M | $152.7M | $145.4M | $140.0M | $142.6M | $138.3M |
| Stockholders' equity | $520.0M | $581.6M | $654.3M | $258.2M | $305.9M | $265.9M | $315.3M | $352.0M |
| Total current assets | $644.4M | $706.0M | $782.1M | $387.0M | $433.4M | $387.7M | $441.0M | $473.0M |
| Total current liabilities | $49.2M | $47.7M | $50.8M | $49.3M | $42.9M | $37.9M | $41.4M | $36.4M |
| Cash & equivalents | $598.6M | $666.7M | $737.1M | $344.8M | $391.1M | $349.7M | $392.1M | $427.2M |
| Accounts receivable | $30.3M | $24.3M | $30.6M | $30.8M | $30.4M | $25.2M | $32.4M | $30.2M |
| Inventory | $3.8M | $3.7M | $3.6M | $3.5M | $3.0M | $3.3M | $3.0M | $2.4M |
| Property, plant & equipment | $19.5M | $18.4M | $19.7M | $17.0M | $10.5M | $10.8M | $9.4M | $10.1M |
| Accounts payable | $7.0M | $8.0M | $4.2M | $6.3M | $5.9M | $4.6M | $4.2M | $4.0M |
| Accrued liabilities | $39.1M | $36.5M | $43.8M | $40.3M | $34.4M | $31.1M | $35.1M | $30.5M |
| Deferred revenue (current) | — | — | — | — | — | $64.0K | $128.0K | $190.0K |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $931.0K | $909.0K | $887.0K | $151.0K | $148.0K | $144.0K | $141.0K | $117.0K |
| Common stock & paid-in capital | $22.0K | $22.0K | $22.0K | $18.0K | $17.0K | $16.0K | $16.0K | $16.0K |
| Retained earnings | -$1.32B | -$1.25B | -$1.16B | -$1.09B | -$1.02B | -$955.1M | -$891.1M | -$842.7M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$67.3M | -$66.0M | -$54.2M | -$50.7M | -$55.2M | -$44.7M | -$39.4M | -$36.6M |
| Investing cash flow | -$3.4M | -$4.7M | -$2.8M | -$6.0M | -$1.1M | -$1.9M | -$202.0K | -$89.0K |
| Financing cash flow | $2.6M | $294.0K | $449.4M | $10.4M | $97.8M | $4.2M | $4.5M | $4.2M |
| Free cash flow | -$70.6M | -$70.7M | -$57.1M | -$56.7M | -$56.5M | -$46.6M | -$39.6M | -$36.6M |
| Capital expenditures | $3.4M | $4.7M | $2.8M | $6.0M | $1.2M | $1.9M | $202.0K | $89.0K |
| Depreciation & amortization | $1.9M | $1.3M | $1.2M | $1.1M | $1.0M | $981.0K | $951.0K | $959.0K |
| Share-based compensation | $14.6M | $15.6M | $11.4M | $11.7M | $9.7M | $10.5M | $7.2M | $6.6M |
| Change in accounts receivable | $5.9M | -$6.3M | -$118.0K | $356.0K | $5.2M | -$7.2M | $2.2M | $3.0K |
| Change in inventory | $89.0K | $173.0K | $76.0K | $449.0K | -$230.0K | $229.0K | $635.0K | -$142.0K |
| Change in accounts payable | $196.0K | $3.7M | -$1.4M | -$1.3M | $1.7M | $7.0K | $112.0K | $297.0K |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Sales/maturities of investments | — | — | — | — | — | — | — | — |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $52.0M | $63.7M | $58.4M | $51.5M | $43.5M |
| Operating income | -$270.0M | -$171.8M | -$82.4M | -$78.7M | -$78.0M |
| Net income | -$265.9M | -$193.5M | -$80.7M | -$71.0M | -$6.6M |
| EPS (diluted) | $-1.42 | $-1.22 | $-1.02 | $-0.97 | $-0.98 |
| EPS (basic) | $-1.42 | $-1.22 | $-1.01 | $-0.92 | $-0.09 |
| Operating margin | -$520 | -$270 | -$141 | -$153 | -$179 |
| Net margin | -$512 | -$304 | -$138 | -$138 | -$15 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $808.1M | $457.9M | $252.1M | $149.3M | $204.9M |
| Total liabilities | $153.7M | $142.6M | $160.9M | $113.9M | $116.9M |
| Stockholders' equity | $654.3M | $315.3M | $91.1M | $35.4M | $88.0M |
| Total current assets | $782.1M | $441.0M | $232.2M | $129.6M | $191.3M |
| Total current liabilities | $50.8M | $41.4M | $34.9M | $31.4M | $26.3M |
| Cash & equivalents | $737.1M | $392.1M | $195.8M | $102.3M | $164.2M |
| Accounts receivable | $30.6M | $32.4M | $26.2M | $21.3M | $21.1M |
| Inventory | $3.6M | $3.0M | $2.3M | $2.0M | $1.2M |
| Property, plant & equipment | $19.7M | $9.4M | $11.7M | $9.9M | $7.0M |
| Accounts payable | $4.2M | $4.2M | $4.4M | $5.1M | $4.6M |
| Accrued liabilities | $43.8M | $35.1M | $28.7M | $24.1M | $20.1M |
| Deferred revenue (current) | — | $128.0K | $255.0K | $576.0K | — |
| Other non-current liabilities | $887.0K | $141.0K | $108.0K | $93.0K | — |
| Common stock & paid-in capital | $22.0K | $16.0K | $12.0K | $8.0K | $8.0K |
| Retained earnings | -$1.16B | -$891.1M | -$697.6M | -$616.8M | -$545.8M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$204.9M | -$134.7M | -$70.2M | -$59.6M | -$65.5M |
| Investing cash flow | -$11.9M | -$1.3M | -$6.1M | -$3.7M | -$1.2M |
| Financing cash flow | $561.7M | $332.1M | $169.8M | $1.5M | $2.9M |
| Free cash flow | -$216.9M | -$136.0M | -$76.3M | -$63.3M | -$66.7M |
| Capital expenditures | $12.0M | $1.3M | $6.1M | $3.7M | $1.2M |
| Depreciation & amortization | $4.3M | $3.8M | $3.0M | $2.1M | $2.4M |
| Share-based compensation | $43.2M | $33.1M | $17.8M | $17.0M | $15.0M |
| Change in accounts receivable | -$1.7M | $6.2M | $4.9M | $190.0K | $8.9M |
| Change in inventory | $524.0K | $735.0K | $331.0K | $724.0K | $49.0K |
| Change in accounts payable | -$887.0K | -$318.0K | $583.0K | -$621.0K | $1.8M |
| Purchases of investments | — | — | — | — | — |
| Sales/maturities of investments | — | — | — | — | — |
| Debt issued | — | — | $82.5M | — | — |
| Debt repaid | — | — | $26.1M | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding OCUL as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 31 filers
Held by These Filers77.4%
Shares Outstanding224,952,428
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| FMR LLC | 32,844,043 | $322.5M | 14.60% | +0.6% | 2026-08-13 |
| Deep Track Capital, LP | 19,686,282 | $193.3M | 8.75% | +0.0% | 2026-08-14 |
| BlackRock, Inc. | 19,376,555 | $190.3M | 8.61% | +20.1% | 2026-08-07 |
| Avoro Capital Advisors LLC | 12,540,000 | $123.1M | 5.57% | +1.8% | 2026-08-14 |
| SUMMER ROAD LLC | 12,208,296 | $119.9M | 5.43% | +2.8% | 2026-08-10 |
| Venrock Adviser, LLC | 10,346,926 | $101.6M | 4.60% | +0.0% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 8,832,595 | $86.7M | 3.93% | +1.3% | 2026-06-30 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 7,623,533 | $74.9K | 3.39% | +29.3% | 2026-08-14 |
| Logos Global Management LP | 5,300,000 | $52.0M | 2.36% | +37.7% | 2026-08-14 |
| State Street Corp | 5,233,282 | $51.4M | 2.33% | +11.1% | 2026-08-07 |
| GEODE CAPITAL MANAGEMENT, LLC | 5,021,092 | $49.3M | 2.23% | +10.9% | 2026-08-12 |
| Point72 Asset Management, L.P. | 3,292,193 | $32.3M | 1.46% | -40.5% | 2026-08-14 |
| DIMENSIONAL FUND ADVISORS LP | 2,783,367 | $27.3M | 1.24% | +328.4% | 2026-08-11 |
| BALYASNY ASSET MANAGEMENT L.P. | 2,270,707 | $22.3M | 1.01% | -15.7% | 2026-08-13 |
| Octagon Capital Advisors LP | 2,075,000 | $20.4M | 0.92% | -34.5% | 2026-08-14 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,973,130 | $19.4M | 0.88% | +23.7% | 2026-06-30 |
| Northern Trust Corp | 1,799,426 | $17.7M | 0.80% | +17.9% | 2026-08-12 |
| Goldman Sachs Group Inc | 1,761,754 | $17.3M | 0.78% | +58.7% | 2026-08-14 |
| Nuveen, LLC | 1,697,274 | $16.7M | 0.75% | +312.9% | 2026-08-11 |
| Woodline Partners LP | 1,667,609 | $16.4M | 0.74% | +0.0% | 2026-08-14 |
| TCG Crossover Management, LLC | 1,647,752 | $16.2M | 0.73% | +0.0% | 2026-08-12 |
| UBS Group AG | 1,551,001 | $15.2M | 0.69% | +2.0% | 2026-08-13 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,550,000 | $15.2M | 0.69% | +0.0% | 2026-08-14 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,533,438 | $15.1M | 0.68% | +4.9% | 2026-08-14 |
| Sixth Street Partners Management Company, L.P. | 1,533,438 | $15.1M | 0.68% | +0.0% | 2026-08-13 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-02-23 to 2026-10-08
Recent transactions
- Insiders have net sold 107,646 shares over the last 182 days, across 0 purchases and 13 sales.
- Most recent: Anderman Todd (Chief Legal Officer) — Open market sale of 11,984 shares on 2026-10-08.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)107,646 sh(13 txns)
Net Shares-107,646
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Anderman Todd | Chief Legal Officer | Open market sale | 2026-10-08 | 11,984 |
| Kaiser Peter | Chief Development Officer | Open market sale | 2026-10-02 | 9,990 |
| Heier Jeffrey S. | Chief Scientific Officer | Open market sale | 2026-10-02 | 10,869 |
| Notman Donald | Chief Operating Officer | Open market sale | 2026-08-31 | 1,099 |
| Dugel Pravin | See Remarks | Gift | 2026-08-25 | 50,092 |
| Nayak Sanjay | Chief Strategy Officer | Open market sale | 2026-08-24 | 1,897 |
| Warden Charles M | Director | Grant / award | 2026-06-10 | 14,000 |
| Graves Adrienne L | Director | Grant / award | 2026-06-10 | 14,000 |
| Robins Jason Shand | Chief Financial Officer | Grant / award | 2026-06-10 | 15,441 |
| Hong Seung Suh | Director | Grant / award | 2026-06-10 | 14,000 |
| LINDSTROM RICHARD L MD | Director | Grant / award | 2026-06-10 | 14,000 |
| RAINES MERILEE | Director | Grant / award | 2026-06-10 | 14,000 |
| Williams Leslie J. | Director | Grant / award | 2026-06-10 | 14,000 |
| Waheed Nadia | Chief Medical Officer | Open market sale | 2026-06-03 | 14,828 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-08 | Anderman Todd | Chief Legal Officer | Open market sale | 11,984 | $7.29 |
| 2026-10-02 | Kaiser Peter | Chief Development Officer | Open market sale | 9,990 | $7.05 |
| 2026-10-02 | Heier Jeffrey S. | Chief Scientific Officer | Open market sale | 10,869 | $7.05 |
| 2026-08-31 | Notman Donald | Chief Operating Officer | Open market sale | 1,099 | $10.24 |
| 2026-08-25 | Dugel Pravin | See Remarks | Gift | 50,092 | $0.00 |
| 2026-08-25 | Dugel Pravin | See Remarks | Gift | 50,092 | $0.00 |
| 2026-08-24 | Kaiser Peter | Chief Development Officer | Open market sale | 3,035 | $10.77 |
| 2026-08-24 | Nayak Sanjay | Chief Strategy Officer | Open market sale | 1,897 | $10.78 |
| 2026-08-24 | Heier Jeffrey S. | Chief Scientific Officer | Open market sale | 3,296 | $10.78 |
| 2026-08-24 | Dugel Pravin | See Remarks | Open market sale | 21,649 | $10.77 |
| 2026-06-16 | Dugel Pravin | See Remarks | Gift | 50,092 | $0.00 |
| 2026-06-16 | Dugel Pravin | See Remarks | Gift | 50,092 | $0.00 |
| 2026-06-10 | Warden Charles M | Director | Grant / award | 14,000 | $0.00 |
| 2026-06-10 | Graves Adrienne L | Director | Grant / award | 14,000 | $0.00 |
| 2026-06-10 | Robins Jason Shand | Chief Financial Officer | Grant / award | 15,441 | $0.00 |
| 2026-06-10 | Hong Seung Suh | Director | Grant / award | 14,000 | $0.00 |
| 2026-06-10 | LINDSTROM RICHARD L MD | Director | Grant / award | 14,000 | $0.00 |
| 2026-06-10 | RAINES MERILEE | Director | Grant / award | 14,000 | $0.00 |
| 2026-06-10 | Williams Leslie J. | Director | Grant / award | 14,000 | $0.00 |
| 2026-06-03 | Waheed Nadia | Chief Medical Officer | Open market sale | 14,828 | $8.27 |
| 2026-05-28 | Dugel Pravin | See Remarks | Gift | 394,696 | $0.00 |
| 2026-05-28 | Dugel Pravin | See Remarks | Gift | 394,696 | $0.00 |
| 2026-05-26 | Dugel Pravin | See Remarks | Open market sale | 21,156 | $8.20 |
| 2026-05-26 | Kaiser Peter | Chief Development Officer | Open market sale | 2,967 | $8.20 |
| 2026-05-26 | Heier Jeffrey S. | Chief Scientific Officer | Open market sale | 3,018 | $8.20 |
| 2026-05-26 | Nayak Sanjay | Chief Strategy Officer | Open market sale | 1,858 | $8.20 |
| 2026-04-09 | Dugel Pravin | See Remarks | Gift | 394,696 | $0.00 |
| 2026-04-09 | Dugel Pravin | See Remarks | Gift | 394,696 | $0.00 |
| 2026-02-23 | Dugel Pravin | See Remarks | Open market sale | 20,056 | $8.28 |
| 2026-02-23 | Kaiser Peter | Chief Development Officer | Open market sale | 2,810 | $8.28 |
| 2026-02-23 | Heier Jeffrey S. | Chief Scientific Officer | Open market sale | 3,057 | $8.28 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 02:28 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-16 | 8-K | 2026-10-14 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-08 | View on SEC.gov → |
| 2026-10-06 | 4 | 2026-10-02 | View on SEC.gov → |
| 2026-10-06 | 4 | 2026-10-02 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-08-26 | 4 | 2026-08-24 | View on SEC.gov → |
| 2026-08-26 | 4 | 2026-08-24 | View on SEC.gov → |
| 2026-08-26 | 4 | 2026-08-24 | View on SEC.gov → |
| 2026-08-26 | 4 | 2026-08-24 | View on SEC.gov → |
| 2026-08-03 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-03 | 8-K | 2026-08-03 | View on SEC.gov → |
| 2026-06-18 | 4 | 2026-06-16 | View on SEC.gov → |
Recent news
Headlines about OCUL (Ocular Therapeutix, Inc.). Links open the publisher — we don’t host full articles.
-
Ocular Therapeutix (OCUL) Stock Dropped, So What Is Driving Attention Now?
Simply Wall Street · 2026-10-20 -
Ocular Therapeutix at chardan healthcare conference: wet amd push advances
Investing.com Nigeria · 2026-10-20 -
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win
Yahoo Finance · 2026-10-20 -
H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy
Investing.com · 2026-10-20 -
OCUL Jun 2027 8.000 call (OCUL270617C00008000) interactive stock chart
Yahoo Finance Australia · 2026-10-20 -
OCUL Jan 2029 8.000 call (OCUL290119C00008000) stock price, news, quote and history
Yahoo Finance Australia · 2026-10-20 -
OCUL Mar 2027 8.000 put (OCUL270319P00008000) stock price, news, quote and history
Yahoo Finance Australia · 2026-10-20 -
$OCUL stock is down 9% today. Here's what we see in our data.
Quiver Quantitative · 2026-10-19
No headlines in this category right now — try “All”.